Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, will participate in the H.C. Wainwright Global Investment Conference on September 14-15 , the Cantor Global Healthcare Conference on September 16 , and the Lake Street Best Ideas Growth Conference on September
|
SAN FRANCISCO, Sept. 9, 2020 /PRNewswire/ -- Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, will participate in the H.C. Wainwright Global Investment Conference on September 14-15, the Cantor Global Healthcare Conference on September 16, and the Lake Street Best Ideas Growth Conference on September 17.
Dr. Richard Chin, Chief Executive Officer, will present and be available for one-on-one meetings. During this time, investors will have the opportunity to discuss recent developments, study results from key therapeutic programs in development, and upcoming milestones. Conference Details: H.C. Wainwright Global Investment Conference Date: September 14-15, 2020 Presentation time: 3:30–3:50p.m. ET, September 15, 2020 Webcast URL: Click here Cantor Global Healthcare Conference Date: September 16, 2020 Presentation time: 2:40–3:10p.m. ET Webcast URL: Click here Lake Street Best Ideas Growth Conference Date: September 17, 2020 An archived version of the above webcasts will be available for 30 days on the KindredBio website. About Kindred Biosciences Kindred Biosciences is a biopharmaceutical company developing innovative biologics focused on saving and improving the lives of pets. Its mission is to bring to pets the same kinds of safe and effective medicines that human family members enjoy. The Company's strategy is to identify targets that have already demonstrated safety and efficacy in humans and to develop therapeutics based on these validated targets for dogs and cats. KindredBio has a deep pipeline of novel biologics in development across many therapeutic classes, alongside state-of-the-art biologics manufacturing capabilities and a broad intellectual property portfolio. For more information, visit: www.kindredbio.com Contact Katja Buhrer
SOURCE Kindred Biosciences, Inc. |
||
Company Codes: NASDAQ-SMALL:KIN |
View original content to download multimedia:
